Celgene Quanticel Research, Inc.

Takeda Pharmaceutical Company Limited

Xinthera, Inc.

Kinnate Biopharma Inc.

Takeda San Diego, Inc.

Alumis Inc.

Other

Quanticel Pharmaceuticals, Inc.

Pierre Fabre Medicament

Achaogen, Inc.

Takeda Pharmaceutical Company Limied

Esker Therapeutics, Inc.

Khora Spv 1, LLC

Stephen W Kaldor

Jeffrey Alan Stafford

Toufike Kanouni

Qing Dong

James Marvin Veal

Young K Chen

Jun Feng

Stephen L Gwaltney

Lynnie Lin Trzoss

Eric A Murphy

Michael Brennan Wallace

Lee D Arnold

Zhiyuan Zhang

John S Tyhonas

Gene Hung

Joseph Robert Pinchman

Bohan Jin

Robert Steven Kania

Amogh Boloor

Jason M Cox

Matthew Michael Kreilein

Juan Manuel Betancort

Benjamin Jones

Sheldon Cao

Andre A Kiryanov

Phillip A Patten

Zhe Li

Zhe Nie

Xiao-Yi Xiao

Zacharia S Cheruvallath

Jason W Brown

Paul Isbester

Anthony R Gangloff

Grant Jackson Palmer

Heinz Ernst Moser

Nicholas Scorah

Betty Lam

Mark Sabat

Phong H Vu

Andrew John Jennings

Qing Lu

Mingnam Tang

Srinivasa Reddy Natala

Robert L Hoffman

Porino Jinjo Va

Michael John Bennett

Paula Alessandra Tavares-Greco

Yan Liu

Joanne Miura

Jerome C Bressi

Beverly Lynn Wolgast

Luckner Gerard Ulysse

Bruce Joseph Elder

Takashi Ichikawa

Robert J Skene

Walter Keung

Craig A Behnke

Prasuna Guntupalli

Mark E Adams

Naoki Tomita

John Tyhonas

Victoria Feher

Brian D Patterson

Ramesh Annasaheb Kasar

Xianchang Gong

Zhlyuan Zhang

Juan Manual Betancort

Eric Murphy

Robert Kania

Dan Wang

Chrisopher McBride

Ramesh Kasar

Srinivasa Ready Natala

Christopher Mcbride

Sheldon X Cao

Feng Zhou

Juan Manuel Bettancort

Amogh Bloor

Bheema R Paraselli

Sanjib Das

Stephen L Ii Gwaltney

Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.

Substituted pyridines as PARP1 inhibitors

Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.

PARP1 inhibitors and uses thereof

Described herein are compounds, for example, substituted 1,2,4-triazoles, that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Substituted 1,2,4-triazoles as TYK2 inhibitors

Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Inhibitors of fibroblast growth factor receptor kinases

Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Inhibitors of RAF kinases

Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.

Pyridinone MK2 inhibitors and uses thereof

Described herein are compounds, for example, 1,2,4-triazole-substituted N-heteroaryl amines, that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors

Described herein are compounds, for example, substituted pyridazines, that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Substituted pyridazines as TYK2 inhibitors

Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer and are of Formula (Ip):

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.

Inhibitors of lysine specific demethylase-1

Described herein are MK2 inhibitors of Formula (II) and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.

MK2 inhibitors and uses thereof

Described herein are azetidine and pyrrolidine PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer and are of Formula I(b)

Azetidine and pyrrolidine PARP1 inhibitors and uses thereof

Inhibtors of RAF kinases

Growing community of inventors

San Diego, CA, United States of America

Stephen W Kaldor